# Tirzepatide Side Effects: What the Research Shows > Tirzepatide side effects as documented in clinical trials, meta-analyses, pharmacovigilance, and the FDA label — gastrointestinal events, gallbladder signals, lean-mass concerns, and the boxed thyroid warning. ## The short version Tirzepatide side effects documented in clinical trials are dominated by gastrointestinal events — nausea, diarrhoea, constipation, and vomiting — concentrated during dose escalation and mostly mild to moderate. That pattern is consistent across every large trial in the programme. The FDA prescribing information also carries a boxed warning about thyroid C-cell tumours seen in rodents; this is a label-mandated caution, not a confirmed human finding. A separate signal — increased risk of gallbladder and biliary disease — is consistently observed across pooled analyses of randomised trials. This page catalogues the safety record as documented in the trials, meta-analyses, and pharmacovigilance data. What people report in community accounts is on the [Tirzepatide effects](/effects) page, clearly labeled as anecdotal. ## Tirzepatide side effects: the gastrointestinal profile Gastrointestinal adverse events are the most common tirzepatide side effects in clinical trials. Nausea, vomiting, diarrhoea, constipation, and decreased appetite emerge primarily during dose escalation and generally ease with continued exposure. A systematic review and meta-analysis of tirzepatide-induced gastrointestinal manifestations (Mishra et al., Cureus, 2023) quantified the incidence of nausea, vomiting, diarrhoea, and decreased appetite across trials [13]. A pharmacovigilance analysis of FAERS data (Q2 2022–Q2 2024) found nausea (27.7%) and diarrhoea (12.8%) were the most frequently reported gastrointestinal adverse events, with a median onset of 16 days and most events occurring within the first three months [14]. A meta-analysis of 13 randomised trials in 26,894 obese participants without diabetes found an overall gastrointestinal adverse-event risk approximately 2.9-fold above placebo (RR 2.94, 95% CI 2.61–3.32) [13]. The state-of-the-art narrative review of GLP-1 receptor agonists and tirzepatide notes that these effects are typically mild to moderate and tend to resolve over time, though they drive the bulk of treatment discontinuations [15]. In SURPASS-2, gastrointestinal adverse events were the most common treatment-emergent adverse events and were mostly mild to moderate [3]. The same pattern was observed across SURMOUNT-1 [4] and SURMOUNT-5 [5]. ## What are the bad side effects of tirzepatide? The safety signals that the regulatory and evidence-appraisal record flags as requiring monitoring or contraindication are: **Boxed warning — thyroid C-cell tumours:** The prescribing information carries a boxed warning derived from rodent studies in which tirzepatide and related incretin compounds caused dose-dependent thyroid C-cell tumours. Whether this translates to humans is not established. Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [10]. A review of the compound's safety profile also notes this as a class-level theoretical association rather than a confirmed human finding [7]. **Gallbladder and biliary disease:** The meta-analysis of nine randomised controlled trials (9,871 participants) found a statistically significant increase in the composite outcome of gallbladder or biliary disease versus controls (relative risk 1.97, 95% CI 1.14–3.42) [6]. A separate meta-analysis of 12 trials found consistent signals for gallbladder and biliary disease and for cholelithiasis (gallstones) [23]. A class-level cardiovascular and tolerability meta-analysis of 99,599 patients also recorded increased gallbladder disorders [31]. Rapid weight loss is a known mechanism for gallstone formation. **Lean-mass loss:** Body-composition data from SURMOUNT-1 (DXA substudy, Look et al., Diabetes Obes Metab, 2025) found approximately 25% of weight lost was lean mass and approximately 75% fat mass [22]. A broader systematic review of incretin-based weight loss across programmes found a median muscle-attributable share near 28% [24]. The functional consequences — whether lean-mass loss impairs physical function — are still being characterised. Resistance exercise is consistently identified as a mitigating strategy. **Pancreatitis:** Acute pancreatitis is a recognised class concern. The dedicated meta-analysis of nine randomised trials found no statistically significant increase versus controls (RR 1.46, 95% CI 0.59–3.61) [6]. A real-world propensity-matched cohort found lower recurrence among tirzepatide users with a prior pancreatitis history [21]. The signal is monitored and label-flagged but not confirmed as an elevated trial-level risk. **Weight regain after stopping:** SURMOUNT-4 demonstrated substantial weight regain when participants switched to placebo after initial treatment, confirming that the metabolic benefits depend on continued use [28]. A post-hoc analysis of SURMOUNT-4 found weight regain was accompanied by worsening of systolic blood pressure and cardiometabolic markers [29]. **Discontinuation rate:** A meta-analysis of three head-to-head trials versus dulaglutide found discontinuation due to adverse events was about 32% higher with tirzepatide, driven by gastrointestinal effects [33]. A FAERS series also identified incorrect dose administration as one of the most frequently reported events [34]. **Hair loss:** Reversible diffuse hair shedding (telogen effluvium) triggered by the physiological stress of rapid weight loss, rather than direct drug toxicity, is case-documented and captured in pharmacovigilance data [29]. ## What are the drawbacks of tirzepatide? The drawbacks of tirzepatide, as the clinical literature records them, fall into three categories: First, tolerability: gastrointestinal side effects require a slow escalation, and a meaningful proportion of patients discontinue because of them [33]. The greater potency of tirzepatide relative to earlier drugs in this class comes with a corresponding tolerability cost. Second, dependency of effect: the weight and metabolic benefits depend on continued treatment. Weight regains on discontinuation are consistent and substantial [28]. This is a chronic therapy, not a course. Third, honest evidence gaps: the long-term cardiovascular outcomes in type 2 diabetes are still being evaluated in SURPASS-CVOT [32]. Much of the highest-quality efficacy evidence is sponsor-funded — standard for a novel drug, but a structural feature of the evidence base worth noting. The lean-mass-loss functional significance, thyroid risk in humans, and optimal patient selection criteria for obesity are all open questions in the published literature. For [Tirzepatide research](/research) into the clinical trial record, see the research page. ## Who cannot take tirzepatide? The prescribing information documents the following contraindications and cautions: **Absolute contraindications:** personal or family history of medullary thyroid carcinoma; Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); known serious hypersensitivity to tirzepatide or any excipient in the formulation [10]. **Not indicated for:** type 1 diabetes mellitus; patients already at their target glycaemic goal with other agents for whom no additional benefit has been assessed; pregnancy (limited data) [10]. **Special caution groups:** people taking sulfonylureas or insulin (increased hypoglycaemia risk, dose adjustment of the concomitant agent may be needed) [10]; people taking oral contraceptives (absorption may be reduced around dose initiations and increases; non-oral or barrier methods recommended during those windows) [10, 26]; people undergoing procedures under sedation or anaesthesia (perioperative fasting guidance and possible gastric ultrasound given the delayed gastric emptying effect) [25]; people with renal impairment (pharmacokinetic data limited; no dose adjustment is currently specified in the label, but close monitoring is warranted) [10]. These are the label's documented populations, not a clinical recommendation. A prescribing physician applies these criteria to an individual patient's full medical history. --- Observational field notes on the tirzepatide trial record — each finding catalogued by evidence type, each gap left plainly unfilled; no clinic behind this desk, no prescription written here.